全球焦虑与相关睡眠障碍治疗行业市场前景及投资研究报告-培训课件外文版2024.5

INDUSTRIES

&

MARKETSAnxiety

and

Related

SleepDisorders:

market

data

&

analysisMarket

InsightsreportJuly2023Table

of

ContentsOverviewAppendixSummary567ProductOverviewAuthor1920MarketDefinitionKeyTakeawaysMarket

NumbersRevenue91215AverageRevenue

per

PatientPatients2MARKET

INSIGHTSThis

report

is

part

ofour

Market

Insights

productGainabetterunderstandingofmarketsacross190+

geographicalentities

–

onaglobal,

regional,country,

and/orstatelevel.

Accessourdatavia

webinterface,download(XLS,

PDF,PPT),or

reports.Benefitfromour48-hourcustomerservice

guarantee.•

10

sectors:

advertising&media,consumers,countries,digital

sector,finance,health,

industrialsector,mobility,andtechnology•

1,000+

markets,

e.g.,

FinTech,Food,or

Robotics•

KPIs,

e.g.,

revenue,marketshares,prices,andvolume•

Features:Compare

countries®ions,

change

currencies,

selectvisualizations,

and/or

customize

downloads•

Usecases:

sales

planning,

investment

decision

support,resourceallocation,andportfolio

management10sectors190+geographicalentities1,000+markets400+reportsFind

out

more

on:https://www.Goto

Market

Insightscom/outlook/3CHAPTER

1OverviewThe

Anxiety

andRelated

Sleep

Disorders

segment

covers

sales

of

the

drugclasses

anxiolytics,

hypnotics

and

sedativesOverview:

SummarySummaryAnxietyandrelated

sleep

disorders

aresome

ofthemost

common

mental

healthdisorders

aroundtheworld.

They

candevelop

differently

from

person

to

person,rangingfrom

generalized

tosocial

andphobicanxietyand

from

obsessivecompulsive

disorder

(OCD)topost-traumatic

disorder

(PTSD).Anxiety

isoften

acauseof

sleeping

problems,

butsleep

deprivationcanalsooften

bethereasonbehindananxietydisorder.Antianxietydrugsare

acornerstone

treatment

fordealing

withanxietydisorders.Themost

common

type

of

prescribed

medications

are

anxiolytics,hypnotics,andsedatives.

Therise

inanxietyprescriptions

hasbeen

particularly

evident

amongyoung

adults.Research

suggeststhatthe

increase

inprescription

rates

is

likelydueto

theadvancements

inthedetection

ofanxietyaswell

astheincreasingacceptance

ofmeditacion,

particularly

inWestern

countries.

Thecurrentapproved

drugshaveshown

to

havehighefficacy

intreatingthedisorder,

yettheresearch

isstillexploring

novel

medications.Theproportion

of

the

worldwide

populationwith

diagnosed

cases

(prevalence)varies

between

countries,

rangingfrom

2.5%

to7%,

withwomen

beingmore

likelytoreport

symptoms

than

men.

There

was,however,

ariseindiagnosed

casesrightafterthe

peak

of

COVID-19,

which

canbeattributedtothe

rise

instresslevels

and

uncertainty

broughtaboutbythe

unprecedented

times.

Thisincreaseindiagnoses

resulted

inaglobalspikeinrevenues

forthe

Anxiety

and

RelatedSleep

Disorders

market

inthe

first

yearof

the

pandemic.5Sources:Market

Insights

2023Anxiety

and

Related

Sleep

Disorders

are

an

important

part

of

the

MentalHealthmarketOverview:

Market

DefinitionMarket

definitionTheAnxietyandRelated

Sleep

Disorders

market

covers

salesof

three

drugclasses:

anxiolytics,hypnotics,andsedatives.

Theseclasses

containdifferenttypesofdrugs,suchasbenzodiazepines,

anticonvulsants,and

antihistamines,thatreduce

anxietyandinsomnia

symptoms

caused

byanxiety.

Thesemedications

mainly

fallinto

thecategory

of

prescription

drugs.Market

valuesrepresent

the

revenues

generated

bymanufacturers

and

are

basedon

retailprices

foreach

drugcategory

includingalldrugs,regardless

ofwhethertheyarereimbursed

or

not.Companyexamples:

Pfizer,

Bristol-Myers

Squibb,GlaxoSmithKline

PLC,

Johnson&

Johnson,and

Merck

&

Co.6Sources:Market

Insights

2023Anxiety

and

Related

Sleep

Disorders

accounted

for23.20%

of

the

Mental

Healthmarket

revenue

in

2022Overview:

Key

Takeaways

and

inscope

/outof

scopeKeyTakeawaysInscopeOutof

scopeRevenue

intheAnxietyandRelated

Sleep

Disorders

market

isprojected

toreachUS$8.51bn

in2023.Thissegment

includes:Thissegment

excludes:Revenue

isexpected

toshow

anannualgrowth

rate(CAGR

(1)

2023-2028)

of0.47%,resultinginamarket

volume

of

US$8.72bn

by2028.•Pharmaceutical

sales

andconsumption

ofanxiolytics•Non-mental

health

related

sleepdisordersInglobalcomparison,

most

revenue

will

begenerated

in

theUnitedStates(US$2,864.00m

in2023).•Pharmaceutical

sales

andconsumption

hypnoticsandsedatives•Any

other

anxiety

medications•PsychotherapyInrelation

to

totalpopulation

figures,per

person

revenues

of

US$24.79

aregenerated

in2023.7Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:CHAPTER

2Market

NumbersAnxiety

and

Related

Sleep

Disorders

revenue

is

estimated

to

increase

at

aCAGR(1)

of

1.0%

from

2016

to

2028Market

Size:

Globalrevenue

forecast

inbillionUS$+1.0%(1)8.78.78.78.68.68.58.48.48.38.08.07.97.820162017201820192020202120222023202420252026202720289Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:With

revenue

of

3.8

billion

US$,

Americas

is

the

biggest

market

among

selectedregions,

in

2022Market

Size:

Regional

Comparison

(1/2)revenue

forecast

inbillionUS$+0.1%(1)3.83.9+1.1%(1)+0.9%(1)2.22.22.12.0+0.3%(1)+0.8%(1)0.40.40.10.12022202820222028202220282022202820222028EuropeAfricaAmericasAsiaAustralia10

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023With

revenue

of

2.85

billion

US$,

United

States

is

the

biggest

market

amongselected

countries,

in

2022Market

Size:

Regional

Comparison

(2/2)revenue

forecast

inbillionUS$+0.2%(1)2.852.89+1.7%(1)-0.9%(1)+0.9%(1)+0.3%(1)0.560.500.380.360.260.280.240.242022202820222028202220282022202820222028United

StatesChinaJapanCanadaFrance11

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023The

average

revenue

per

patient

in

the

Anxiety

and

Related

Sleep

Disorderssegment

is

estimated

to

decrease

from2016

to

2028Market

Size:

Globalaverage

revenue

perpatientforecast

inUS$3027.327.027.026.525.925.325.024.824.524.223.825201510523.523.10201620172018201920202021202220232024202520262027202812

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Americas

have

the

biggest

average

revenue

per

patient

in

2022Market

Size:

Regional

Comparison

(1/2)average

revenue

perpatientforecast

inUS$8072.371.067.370605040302010064.761.359.057.756.543.755.443.854.543.753.643.652.843.452.043.245.436.943.837.644.232.143.432.543.429.843.229.942.636.428.827.926.925.912.525.024.112.28.512.58.212.67.812.47.312.67.112.76.912.66.712.66.512.46.012.25.811.49.211.68.56.22016201720182019202020212022202320242025202620272028AmericasEuropeAustraliaAsiaAfrica13

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023With

an

average

revenue

per

patient

of

122.3

US$,

United

States

are

the

biggestmarket

among

selected

countries,

in

2022Market

Size:

Regional

Comparison

(2/2)average

revenue

perpatientforecast

inUS$157.0156.616014012010080142.4133.8129.4122.8122.3121.0119.8118.7117.7116.8116.066.652.264.852.363.252.662.448.861.751.561.548.160.247.859.847.559.447.259.046.958.646.558.346.257.945.86040

31.32031.27.030.78.329.38.727.79.526.110.126.110.425.910.825.711.025.411.225.211.425.011.524.911.66.302016201720182019202020212022202320242025202620272028UnitedStatesUnitedKingdomFranceGermanyChina14

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023The

number

of

patients

of

Anxiety

and

Related

Sleep

Disorders

medication

isestimated

to

increase

from

2016

to

2028Market

Size:

Globalpatientsforecast

inmillion40035030025020015010050377.4370.7364.0357.3350.4343.4336.5329.8323.2298.0295.1291.7287.60201620172018201920202021202220232024202520262027202815

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023In2022,

Asia

has

more

Anxiety

and

Related

Sleep

Disorder

patients

comparedto

other

selected

regionsMarket

Size:

Regional

Comparison

(1/2)patientsforecast

inmillion200183.6180.9178.2175.4172.7169.9167.1164.6162.0150.6151.7151.7148.41501005072.061.673.263.874.366.169.457.370.859.468.055.266.553.163.549.264.951.157.844.141.954.254.956.143.141.949.841.940.942.041.948.448.949.447.946.446.947.445.71.81.51.61.61.61.81.92.02.12.22.32.42.502016201720182019202020212022202320242025202620272028AsiaAmericasAfricaEuropeAustralia16

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023With

48.3

million

patients,

China

is

the

biggest

market

among

selectedcountries,

in

2022Market

Size:

Regional

Comparison

(2/2)patientsforecast

inmillion48.848.948.520.648.448.348.348.248.248.148.148.047.647.9504540353025201510524.56.524.76.624.96.624.06.424.36.523.76.423.36.323.06.322.66.219.25.618.35.618.55.65.74.53.34.44.44.44.95.25.34.95.05.05.15.25.33.63.83.93.94.04.120264.14.220283.23.220173.33.72021Germany0201620182019China2020France20222023202420252027United

KingdomUnited

States17

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023CHAPTER

3AppendixMARKET

INSIGHTSMarket

Insights

–

market

data,forecasts,

and

qualitative

insightsGainabetterunderstandingofmarketsacross190+

geographicalentities

–

onaglobal,

regional,country,

and/orstatelevel.

Accessourdatavia

webinterface,download(XLS,

PDF,PPT),or

reports.Benefitfromour48-hourcustomerservice

guarantee.•

10

sectors:

advertising&media,consumers,countries,digital

sector,finance,health,

industri